DEA Temporarily Relaxes Telemedicine Standards for Prescribing Buprenorphine During COVID-19 Outbreak

| April 10, 2020

The Drug Enforcement Administration (DEA) has temporarily relaxed the federal requirements for prescribing buprenorphine for opioid use disorder (OUD) via telemedicine during the COVID-19 public health emergency. As a general rule, the federal Controlled Substances Act (CSA) requires a valid prescription before a controlled prescription medication may be delivered, distributed, or dispensed by means of […]

FORE Issues Opinion Letter on Prescribing Buprenorphine with Telemedicine During COVID-19 Outbreak

| April 7, 2020

The COVID-19 outbreak has presented extraordinary challenges in prescribing buprenorphine to new and existing patients with opioid use disorder (OUD). Telemedicine presents an opportunity to reach these patients and promote continuity of care; however, rapidly evolving circumstances have caused confusion among many practitioners as to their rights and obligations under federal law when prescribing controlled […]